Arcis Biotechnology and Teleflex Sign License Agreement | Financial Buzz

Arcis Biotechnology and Teleflex Sign License Agreement

Arcis Biotechnology (“Arcis”), the nucleic acid sample preparation
solution provider, today announced it has signed a technology access
agreement with Teleflex Incorporated, a New York Stock Exchange listed
company (NYSE: TFX). Teleflex will harness Arcis’ advanced nucleic acid
sample preparation chemistry in the development of a novel technology,
which it believes will be disruptive, and is intended to empower
clinicians and drive better patient outcomes.

Arcis’ product portfolio offers the possibility of earlier, more
accurate diagnostics testing from a variety of sample types, using its
rapid, two-step nucleic acid extraction and preservation technology. The
company has an extensive patent portfolio covering DNA and RNA
extraction and preservation for downstream processing by qPCR, RT-qPCR
and sequencing in under three minutes. The speed, simplicity and
low-resource requirements of the platform provides an ideal solution for
point-of-care, microfluidics or field-based testing, and supports both
companies’ drive to improve diagnostic testing and benefit patients and
healthcare professionals.

Peter Whitehurst, CEO, Arcis Biotechnology, commented: “We are
delighted that Teleflex has chosen to leverage the speed and simplicity
of our sample preparation technology in its product development
programme. Obtaining genetic material from biological samples is a
critical step in molecular biology processes, and we are excited to see
our platform being applied across many different and growing markets.”

This news follows the announcement of a successful £1.25 million
investment round and additional £0.5 million overfunding hosted by
crowdfunding platform Capital Cell. Following Arcis’ recent development
successes in the isolation and preservation of microRNA (miRNA) and
oncology biomarkers, Arcis is now looking to invest further in R&D,
product development, and to drive international business expansion. The
additional £0.5 million from the Capital Cell funding round will
underpin the Company’s projected revenue growth and associated working
capital requirements in the next two years.

Details of the Arcis Biotechnology investment round can be found here:

View source version on